{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:30:32Z","timestamp":1792290632136,"version":"4.4.0"},"reference-count":51,"publisher":"Jaypee Brothers Medical Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,22]]},"DOI":"10.5005\/jp-journals-10018-1344","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T07:06:02Z","timestamp":1634886362000},"page":"59-70","source":"Crossref","is-referenced-by-count":5,"title":["HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis"],"prefix":"10.5005","volume":"11","author":[{"given":"JC","family":"Aguilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh MF","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurina","family":"Cinza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelvis","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Penton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamun A","family":"Mahtab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoel A","family":"Fleites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bequet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elieser","family":"Marrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritania","family":"Vizca\u00edno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idelsis","family":"Esquivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Sin-Mayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrahan","family":"Beato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana G","family":"Galarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yssel","family":"Mendoza-Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Cana\u00e1n-Haden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Oquendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo E","family":"Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena L","family":"Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"1. Bugra A, Das T, Arslan MN, et al. Postmortem pathological changes in extrapulmonary organs in SARS-CoV-2 rt-PCR\u2013positive cases: a single-center experience. Irish J Med Sci (1971) 2021:1\u201311. DOI: 10.1007\/s11845-021-02638-8.","DOI":"10.1007\/s11845-021-02638-8"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"2. Damiani S, Fiorentino M, De Palma A, et al. Pathological post-mortem findings in lungs infected with SARS-CoV-2. J Pathol 2021;253(1): 31\u201340. DOI: 10.1002\/path.5549.","DOI":"10.1002\/path.5549"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"3. Walensky RP, Del Rio C. From mitigation to containment of the COVID-19 pandemic: putting the SARS-CoV-2 genie back in the bottle. JAMA 2020;323(19):1889\u20131890. DOI: 10.1001\/jama.2020.6572.","DOI":"10.1001\/jama.2020.6572"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"4. Sultana J, Crisafulli S, Gabbay F, et al. Challenges for drug repurposing in the COVID-19 pandemic era. Front Pharmacol 2020;11:588654. DOI: 10.3389\/fphar.2020.588654.","DOI":"10.3389\/fphar.2020.588654"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"5. Chaudhry R, Dranitsaris G, Mubashir T, et al. A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes. EClinicalMedicine. 2020:100464. DOI: 10.1016\/j.eclinm.2020.100464.","DOI":"10.1016\/j.eclinm.2020.100464"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"6. Ahmad T, Chaudhuri R, Joshi MC, et al. COVID-19: The emerging immunopathological determinants for recovery or death. Front Microbiol 2020;11:588409. DOI: 10.3389\/fmicb.2020.588409.","DOI":"10.3389\/fmicb.2020.588409"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"7. Islam MA, Mazumder MA, Akhter N, et al. Extraordinary survival benefits of severe and critical patients with COVID-19 by immune modulators: the outcome of a clinical trial in Bangladesh. Euroasian J Hepatogastroenterol 2020;10(2):68\u201375. DOI: 10.5005\/jp-journals-10018-1327.","DOI":"10.5005\/jp-journals-10018-1327"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"8. Cortegiani A, Ippolito M, Greco M, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology 2021;27(1):52\u201366. DOI: 10.1016\/j.pulmoe.2020.07.003.","DOI":"10.1016\/j.pulmoe.2020.07.003"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"9. Kikkert M. Innate immune evasion by human respiratory RNA viruses. J Innate Immun 2020;12(1):4\u201320. DOI: 10.1159\/000503030.","DOI":"10.1159\/000503030"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"10. Thorne LG, Bouhaddou M, Reuschl AK, et al. Evolution of enhanced innate immune evasion by the SARS-CoV-2 B. 1.1. 7 UK variant. bioRxiv 2021. DOI: 10.1101\/2021.06.06.446826.","DOI":"10.1101\/2021.06.06.446826"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"11. Fern\u00e1ndez G, Sanchez AL, Jerez E, et al. Five-year follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac. Euroasian J Hepatogastroenterol 2018;8(2):133. DOI: 10.5005\/jp-journals-10018-1279.","DOI":"10.5005\/jp-journals-10018-1279"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"12. Al-Mahtab M, Akbar SM, Aguilar JC, et al. Therapeutic potential of a combined hepatitis B surface antigen and core antigen vaccine in patients with chronic hepatitis B. Hepatol Int 2013;7(4):981\u2013989. DOI: 10.1007\/s12072-013-9486-4.","DOI":"10.1007\/s12072-013-9486-4"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"13. Al Mahtab M, Akbar SMF, Aguilar JC, et al. Treatment of chronic hepatitis B na\u00efve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS One 2018;13(8):e0201236. DOI: 10.1371\/journal.pone.0201236.","DOI":"10.1371\/journal.pone.0201236"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"14. Yoshida O, Akbar SM, Kohara M, et al. Induction of anti-HBs and reduction of HBs antigen by nasal administration of a therapeutic vaccine containing HBs and HBc antigen (NASVAC) in patients with chronic hepatitis B. Boston, MA, USA: American Association for Study of the Liver; 2019.","DOI":"10.2139\/ssrn.3741248"},{"key":"ref=15","unstructured":"15. Hiasa Y, Yoshida O, Guillen G, et al. The HB vaccine containing HBs and HBc antigen (NASVAC) can effectively induce anti-HBs antibody in non-responders to the prophylactic vaccine. Boston, MA, USA: American Association for Study of the Liver; 2019."},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"16. Yoshida O, Imai Y, Akbar SMF, et al. HBsAg reduction by nasal administration of A therapeutic vaccine containing HBsAg and HBcAg (NASVAC) in a patients with chronic HBV infection: the results of 18 months follow-up. The Liver Meeting, AASLD, November 13\u201316, 2020.","DOI":"10.1016\/S0168-8278(20)32212-1"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"17. Akbar SMF, Mahtab MA, Aguilar JC, et al. Repurposing NASVAC, a Hepatitis B therapeutic vaccine, for pre- and post-exposure prophylaxis of SARS-CoV-2 infection. J Antivir Antiretrovir 2021;13 (20):1000004. (S20:004). Available from: https:\/\/doi.org\/10.21203\/rs.3.rs-438628\/v1.","DOI":"10.21203\/rs.3.rs-438628\/v1"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"18. Mudgal R, Nehul S, Tomar S. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Hum Vaccin Immunother 2020;16(12): 2921\u20132931. DOI: 10.1080\/21645515.2020.1805992.","DOI":"10.1080\/21645515.2020.1805992"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"19. Burki T. Behind Cuba's successful pandemic response. Lancet Infect Dis 2021;21(4):465\u2013466. DOI: 10.1016\/S1473-3099(21)00159-6.","DOI":"10.1016\/S1473-3099(21)00159-6"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"20. Xu J, Yang Y, Sun J, et al. Expression of Toll-like receptors and their association with cytokine responses in peripheral blood mononuclear cells of children with acute rotavirus diarrhoea. Clin Exp Immunol 2006;144(3):376\u2013381. DOI: 10.1111\/j.1365-2249.2006.03079.x.","DOI":"10.1111\/j.1365-2249.2006.03079.x"},{"key":"ref=21","unstructured":"21. Patent Application: CU 2020-0028: Priority date: 20.04.2020. International presentation date: 20.04.2021.Viral nucleoproteins and formulations thereof."},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"22. Cooper A, Tal G, Lider O, et al. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol 2005;175(5):3165\u20133176. DOI: 10.4049\/jimmunol.175.5.3165.","DOI":"10.4049\/jimmunol.175.5.3165"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"23. Lee BO, Tucker A, Frelin L, et al. Interaction of the hepatitis B core antigen and the innate immune system. J Immunol 2009;182(11):6670\u20136681. DOI: 10.4049\/jimmunol.0803683.","DOI":"10.4049\/jimmunol.0803683"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"24. Kumaki Y, Salazar AM, Wandersee MK, et al. Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol\u00ae(Poly IC: LC), in a lethal SARS-CoV-infected BALB\/c mouse model. Antiviral Res 2017;139:1\u201312. DOI: 10.1016\/j.antiviral.2016.12.007.","DOI":"10.1016\/j.antiviral.2016.12.007"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"25. Zhao J, Wohlford-Lenane C, Zhao J, et al. Intranasal treatment with poly (I\u2022C) protects aged mice from lethal respiratory virus infections. J Virol 2012;86(21):11416\u201311424. DOI: 10.1128\/JVI.01410-12.","DOI":"10.1128\/JVI.01410-12"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"26. Prasad K, Khatoon F, Rashid S, et al. Targeting hub genes and pathways of innate immune response in COVID-19: a network biology perspective. Int J Biol Macromol 2020;163:1\u20138. DOI: 10.1016\/j.ijbiomac.2020.06.228.","DOI":"10.1016\/j.ijbiomac.2020.06.228"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"27. Aich P, Wilson HL, Kaushik RS, et al. Comparative analysis of innate immune responses following infection of newborn calves with bovine rotavirus and bovine coronavirus. J Gen Virol 2007;88(10):2749\u20132761. DOI: 10.1099\/vir.0.82861-0.","DOI":"10.1099\/vir.0.82861-0"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"28. Nelemans T, Kikkert M. Viral innate immune evasion and the pathogenesis of emerging RNA virus infections. Viruses 2019;11(10):961. DOI: 10.3390\/v11100961.","DOI":"10.3390\/v11100961"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"29. Bagchi A, Herrup EA, Warren HS, et al. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol 2007;178(2):1164\u20131171. DOI: 10.4049\/jimmunol.178.2.1164.","DOI":"10.4049\/jimmunol.178.2.1164"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"30. Zhu Q, Egelston C, Gagnon S, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010;120(2): 607\u2013616. DOI: 10.1172\/JCI39293.","DOI":"10.1172\/JCI39293"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"31. Zhu Q, Egelston C, Vivekanandhan A, et al. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci 2008;105(42):16260\u201316265. DOI: 10.1073\/pnas.0805325105.","DOI":"10.1073\/pnas.0805325105"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"32. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med 2020;173(8):623\u2013631. DOI: 10.7326\/M20-4207.","DOI":"10.7326\/M20-4207"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"33. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020;383(6):517\u2013525. DOI: 10.1056\/NEJMoa2016638.","DOI":"10.1056\/NEJMoa2016638"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"34. Curtis N, Sparrow A, Ghebreyesus TA, et al. Considering BCG vaccination to reduce the impact of COVID-19. Lancet 2020;395(10236):1545\u20131546. DOI: 10.1016\/S0140-6736(20)31025-4.","DOI":"10.1016\/S0140-6736(20)31025-4"},{"key":"ref=35","unstructured":"35. Grange JM. Complications of bacille Calmette-Gu\u00e9rin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health 1998;1(2):84\u201388. PMID: 9644119."},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"36. S\u00e1nchez Ram\u00f3n S, Manzanares M, Candelas G. MUCOSAL anti-infections vaccines: beyond conventional vaccines. Reumatol Clin 2020;16(1):49\u201355. DOI: 10.1016\/j.reuma.2018.10.012.","DOI":"10.1016\/j.reumae.2018.10.020"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"37. S\u00e1nchez-Ram\u00f3n S, Conejero L, Netea MG, et al. Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. Front Immunol 2018;9:2936. DOI: 10.3389\/fimmu.2018.02936.","DOI":"10.3389\/fimmu.2018.02936"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"38. S\u00e1nchez-Ram\u00f3n S, P\u00e9rez de Diego R, Dieli-Crimi R, et al. Extending the clinical horizons of mucosal bacterial vaccines: current evidence and future prospects. Curr Drug Targets 2014;15(12):1132\u20131143. DOI: 10.2174\/1389450115666141020160705.","DOI":"10.2174\/1389450115666141020160705"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"39. Alecsandru D, Valor L, S\u00e1nchez-Ram\u00f3n S, et al. Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol 2011;164(1):100\u2013107. DOI: 10.1111\/j.1365-2249.2011.04320.x.","DOI":"10.1111\/j.1365-2249.2011.04320.x"},{"key":"ref=40","unstructured":"40. Altimmune: waiting for their next move against COVID-19. News article. 16.06.2020. Available from: https:\/\/ir.altimmune.com\/investors\/news-articles."},{"key":"ref=41","unstructured":"41. Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1\/2 Clinical Trial of T-COVID\u2122 in Outpatients with Early COVID-19. Press release. 29.06.2020. Available from: www.altimmune.com."},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"42. Metcalf TU, Cubas RA, Ghneim K, et al. Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell 2015;14(3):421\u2013432. DOI: 10.1111\/acel.12320.","DOI":"10.1111\/acel.12320"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"43. Arunachalam PS, Wimmers F, Mok CK, et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 2020;369(6508):1210\u20131220. DOI: 10.1126\/science.abc6261.","DOI":"10.1126\/science.abc6261"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"44. Lobaina Y, Hardtke S, Wedemeyer H, et al. In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol 2015;63(2):320\u2013327. DOI: 10.1016\/j.molimm.2014.08.003.","DOI":"10.1016\/j.molimm.2014.08.003"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"45. Akbar SM, Yoshida O, Chen S, et al. Immune modulator and antiviral potential of DCs pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection. Antivir Ther 2010;15(6):887\u2013895. DOI: 10.3851\/IMP1637.","DOI":"10.3851\/IMP1637"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"46. Monk PD, Marsden RJ, Tear VJ, et al. Inhaled Interferon Beta COVID-19 Study Group. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2021;9(2):196\u2013206. DOI: 10.1016\/S2213-2600(20)30511-7.","DOI":"10.1016\/S2213-2600(20)30511-7"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"47. Akbar SMF, Al Mahtab M, Aguilar JC, et al. Role of pegylated interferon in patients with chronic liver diseases in the context of SARS-CoV-2 Infection. Euroasian J Hepatogastroenetrol 2021;11(1):27\u201331. DOI: 10.5005\/jp-journals-10018-1341.","DOI":"10.5005\/jp-journals-10018-1341"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"48. Varchetta S, Mele D, Oliviero B, et al. Unique immunological profile in patients with COVID-19. Cell Mol Immunol 2021;18(3):604\u2013612. DOI: 10.1038\/s41423-020-00557-9.","DOI":"10.1038\/s41423-020-00557-9"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"49. Sariol CA, Mart\u00ednez MI, Rivera F, et al. Decreased dengue replication and an increased anti-viral humoral response with the use of combined Toll-like receptor 3 and 7\/8 agonists in macaques. PLoS One 2011;6(4):e19323. DOI: 10.1371\/journal.pone.0019323.","DOI":"10.1371\/journal.pone.0019323"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"50. Yuan MM, Xu YY, Chen L, et al. TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis. BMC Cancer 2015;15(1):1\u20136. DOI: 10.1186\/s12885-015-1262-5.","DOI":"10.1186\/s12885-015-1262-5"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"51. Bonnin M, Fares N, Testoni B, et al. Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis. J Hepatol 2019;71(4):763\u2013772. DOI: 10.1016\/j.jhep.2019.05.031.","DOI":"10.1016\/j.jhep.2019.05.031"}],"container-title":["Euroasian Journal of Hepato-Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ejohg.com\/doi\/pdf\/10.5005\/jp-journals-10018-1344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T09:38:06Z","timestamp":1657186686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejohg.com\/doi\/10.5005\/jp-journals-10018-1344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021]]}},"alternative-id":["10.5005\/jp-journals-10018-1344"],"URL":"https:\/\/doi.org\/10.5005\/jp-journals-10018-1344","relation":{},"ISSN":["2231-5047","2231-5128"],"issn-type":[{"value":"2231-5047","type":"print"},{"value":"2231-5128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}